paigeai

Paige details first AI pathology tech with clinical-grade accuracy in new research paper

Researchers associated with Memorial Sloan Kettering Cancer Center and medical tech and computational pathology startup Paige have published a new article in the peer-reviewed medical journal Nature
Sloan Kettering’s Cozy Deal With Start-Up Ignites a New Uproar

Sloan Kettering’s Cozy Deal With Start-Up Ignites a New Uproar

At Memorial Sloan Kettering Cancer Center in Manhattan, doctors and staff objected to a for-profit venture that could be lucrative for a few leading researchers and board members.
Sloan Kettering’s Cozy Deal With Start-Up Ignites a New Uproar

Sloan Kettering’s Cozy Deal With Start-Up Ignites a New Uproar

At Memorial Sloan Kettering Cancer Center in Manhattan, doctors and staff objected to a for-profit venture that could be lucrative for a few leading researchers and board members.
Sloan Kettering’s Cozy Deal With Start-Up Ignites a New Uproar

Sloan Kettering’s Cozy Deal With Start-Up Ignites a New Uproar

At Memorial Sloan Kettering Cancer Center in Manhattan, doctors and staff objected to a for-profit venture that could be lucrative for a few leading researchers and board members.
Sloan Kettering’s Cozy Deal With Start-Up Ignites a New Uproar

Sloan Kettering’s Cozy Deal With Start-Up Ignites a New Uproar

At Memorial Sloan Kettering Cancer Center in Manhattan, doctors and staff objected to a for-profit venture that could be lucrative for a few leading researchers and board members.
Sloan Kettering’s Cozy Deal With Start-Up Ignites a New Uproar

Sloan Kettering’s Cozy Deal With Start-Up Ignites a New Uproar

At Memorial Sloan Kettering Cancer Center in Manhattan, doctors and staff objected to a for-profit venture that could be lucrative for a few leading researchers and board members.
Sloan Kettering’s Cozy Deal With Start-Up Ignites a New Uproar

Sloan Kettering’s Cozy Deal With Start-Up Ignites a New Uproar

At Memorial Sloan Kettering Cancer Center in Manhattan, doctors and staff objected to a for-profit venture that could be lucrative for a few leading researchers and board members.